Levetiracetam Effective as Episodic Migraine Prophylactic
Insufficient evidence is available to determine the efficacy of levetiracetam as a chronic migraine prophylactic.
Approximately half of patients with migraine have kinesiophobia, and the condition is associated with greater severity, not presence of cutaneous allodynia.
In a retrospective analysis, investigators assessed the effects of topical trigger point treatments on headache symptoms in patients with migraine.
Researchers showed high migraine induction capabilities with calcitonin gene-related peptide (CGRP) in people with migraine who responded to erenumab treatment compared to data from previous CGRP provocation experiments.